We are live on ! Find out more
HQL

abrdn Life Sciences Investors

55 hedge funds and large institutions have $60.1M invested in abrdn Life Sciences Investors in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

85% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 13

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

6% more funds holding

Funds holding: 5255 (+3)

1.73% more ownership

Funds ownership: 12.71%14.44% (+1.7%)

4% more capital invested

Capital invested by funds: $57.9M → $60.1M (+$2.17M)

Holders
55
Holders Change
+3
Holders Change %
+5.77%
% of All Funds
1.25%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
9
Increased
24
Reduced
13
Closed
6
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q4 2017 in Review

55 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2017, worth a combined $60.1M — up 3.8% from $57.9M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new HQL positions and 6 closed out — a net gain of 3 holders — while 24 added to existing stakes and 13 trimmed.

The largest buyer was Raymond James & Associates, adding an estimated $2.82M. The largest seller was William Blair & Company, exiting entirely with an estimated $1.2M sold.

  • 55 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2017, up from 52 in Q3 2017.
  • Funds reported $60.1M of abrdn Life Sciences Investors stock for Q4 2017, up 3.8% quarter-over-quarter.
  • 9 funds opened new abrdn Life Sciences Investors positions in Q4 2017 and 6 closed out, a net change of +3 holders.
  • The largest abrdn Life Sciences Investors buyer in Q4 2017 was Raymond James & Associates, an estimated $2.82M added.
  • The largest abrdn Life Sciences Investors seller in Q4 2017 was William Blair & Company, an estimated $1.2M sold.

Based on aggregated 13F filings for Q4 2017.